share_log

阳光诺和(688621.SH)：公司目前拥有3.63万平方米的研发实验室，已投入使用的实验室面积超过80%

Sunshine Novo (688621.SH): The company currently has 36,300 square meters of R&D laboratory, with more than 80% of the laboratory area already in use

Gelonghui Finance ·  Jan 2 03:35

Gelonghui, January 2丨Sunshine Nuohe (688621.SH) received a survey from specific subjects and said that the company currently has 36,300 square meters of R&D laboratory, and more than 80% of the laboratory area has been put into use. The company has established a synthesis laboratory, testing laboratory, microbiology laboratory, etc. at its headquarters in Changping, Beijing, including a laboratory to develop various dosage forms; Beijing Fengtai has built a clinical phase I-III trial center and a small chemical molecule and biomacromolecule PK/PD analysis laboratory; Beijing Daxing and Yizhuang International Biomedical Park have each established pediatric drug platforms and TDS drug laboratories, which have various reserves for the use of pediatric diseases, gel patches, hot melt patches, and solvent stickers; Chengdu has established a Novo and Shengtai Innovative Drug Research and Development Laboratory, which is mainly responsible for the development of innovative drugs developed by the company itself. It has strong advantages in innovative peptide/nucleic acid drug research and development and development of complex injectable formulations; Wuxi has established Novo and Billiton's improved drug research and development laboratory, which is mainly responsible for the company's self-developed and improved new drug types, focusing on microsphere preparations, especially long-acting liquid formulations, complex solid preparations and oral controlled-release formulations; Shanghai has established a new pre-clinical research division with leading positions in vivo and in vitro pharmacology research, humanized animals, immunology research, and biopharmaceutical immunogenicity analysis.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment